Andere Kunden interessierten sich auch für
![Affordability vs Eligibility in HCV patients]( "Affordability vs Eligibility in HCV patients")
Affordability vs Eligibility in HCV patients23,99 €![Integrated clinical approach to intractable diseases]( "Integrated clinical approach to intractable diseases")
Integrated clinical approach to intractable diseases38,99 €![Antiviral Methods and Protocols]( "Antiviral Methods and Protocols")
Antiviral Methods and Protocols75,99 €![Antiviral Strategies]( "Antiviral Strategies")
Antiviral Strategies220,99 €![The history and the future of medicinal plants]( "The history and the future of medicinal plants")
The history and the future of medicinal plants32,99 €![The target to mediate Nitazoxanide's anti-HCV effect. In-silico study]( "The target to mediate Nitazoxanide's anti-HCV effect. In-silico study")
The target to mediate Nitazoxanide's anti-HCV effect. In-silico study32,99 €![Whey protein products attenuate liver fibrosis]( "Whey protein products attenuate liver fibrosis")
Whey protein products attenuate liver fibrosis42,99 €
Hepatitis is one of the major public health problems. Chronic infection with hepatitis results in progressive liver disease leading to cirrhosis and its complications which include hepatocellular carcinoma.The availability of animal models relevant to apoptosis may facilitate the identification of potential therapies. An established model for studying acute liver failure is by the co-administration of the hepatocyte-specific transcriptional inhibitor D-galactosamine (GalN) and the bacterial endotoxin lipopolysaccharide (LPS).This model of liver damage most closely resembles the changes observed during human hepatitis, and thus provides a useful system for screening and investigating drugs that can be used in the treatment of disease.